Jeffrey Cohen

John Vandermosten

Anita Dushyanth

Brian Jeep

- Tenpoint Therapeutics, Ltd. will participate in **four investor conferences** in October and November 2025, with CEO Henric Bjarke presenting at the Stifel Healthcare Conference on **November 12**.  **[34956_f5c8ebabe88d4f869f9a1c9292e6e51a_0]** 
- The company's lead investigational asset, **BRIMOCHOL™ PF**, a combination therapy for presbyopia, has a Prescription Drug User Fee Act (PDUFA) date of **January 28, 2026**.  **[34956_f5c8ebabe88d4f869f9a1c9292e6e51a_0]** 
- Tenpoint Therapeutics is actively preparing for a **commercial launch of BRIMOCHOL™ PF in the first half of 2026**.  **[34956_f5c8ebabe88d4f869f9a1c9292e6e51a_0]**

Tenpoint Therapeutics Announces Participation in Investor Conferences and BRIMOCHOL™ PF Milestones

- The European Patent Office (EPO) has issued an Intention to Grant a patent to Tenax Therapeutics, Inc. for the use of **levosimendan** in pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF).  **[34956_0001654954-25-010792_tennx_ex991.htm:0]** **[34956_0001654954-25-010792_tennx_8k.htm:1]** 
- This patent will provide intellectual property protection in Europe for **TNX-103 (oral levosimendan)**, other formulations, and its active metabolites, through at least **December 2040**, with potential for further extension.  **[34956_0001654954-25-010792_tennx_ex991.htm:0]** 
- The patent covers various routes of administration, active metabolites (OR1896 and OR1855), a wide range of doses, and use in combination with other cardiovascular drugs for PH-HFpEF.  **[34956_0001654954-25-010792_tennx_ex991.htm:0]** 
- This IP protection supports the company's global intellectual property portfolio and is timely as Tenax prepares to initiate its second registrational **Phase 3 study, LEVEL-2**, which will recruit patients across Europe.  **[34956_0001654954-25-010792_tennx_ex991.htm:0]**

TENAX THERAPEUTICS (TENX)